{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T04:30:32Z","timestamp":1776659432948,"version":"3.51.2"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jtct.2022.03.009","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:47:47Z","timestamp":1649378867000},"page":"321.e1-321.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Clinical Significance of BCR-ABL1 Mutations in Patients With Philadelphia Chromosome\u2013Positive Chronic Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7780-4459","authenticated-orcid":false,"given":"Takayoshi","family":"Tachibana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8661-3179","authenticated-orcid":false,"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Takada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Singo","family":"Yano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiko","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8718-2024","authenticated-orcid":false,"given":"Takafumi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-2870","authenticated-orcid":false,"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6556-2894","authenticated-orcid":false,"given":"Tokiko","family":"Nagamura-Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.03.009_bib0001","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"Suppl 2)","key":"10.1016\/j.jtct.2022.03.009_bib0002","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1007\/s00277-015-2322-2","article-title":"A review of the European LeukemiaNet recommendations for the management of CML","volume":"94","author":"Baccarani","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2022.03.009_bib0003","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.03.009_bib0004","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and resistance to BCR-ABL1-targeted therapies","volume":"37","author":"Braun","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtct.2022.03.009_bib0005","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2022.03.009_bib0006","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1016\/S2352-3026(19)30027-4","article-title":"Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study","volume":"6","author":"Kizilors","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2022.03.009_bib0007","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3324\/haematol.2010.034173","article-title":"Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis","volume":"96","author":"Soverini","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.03.009_bib0008","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/cncr.28522","volume":"120","author":"Soverini","year":"2014","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.jtct.2022.03.009_bib0009","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.1016\/j.clml.2018.06.031","article-title":"Comparison of frequency and sensitivity of BCR-ABL1 kinase domain mutations in Asian and white patients with imatinib-resistant chronic-phase chronic myeloid leukemia","volume":"18","author":"Kim","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jtct.2022.03.009_bib0010","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1007\/s11033-019-04816-5","article-title":"ABL1 tyrosine kinase domain mutations in chronic myeloid leukemia treatment resistance","volume":"46","author":"Vacarean-Trandafir","year":"2019","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.jtct.2022.03.009_bib0011","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13045-019-0815-5","article-title":"Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper","volume":"12","author":"Soverini","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtct.2022.03.009_bib0012","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtct.2022.03.009_bib0013","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.03.009_bib0014","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.03.009_bib0015","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1182\/blood-2011-07-367326","article-title":"Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias","volume":"118","author":"Nicolini","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.03.009_bib0016","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1002\/cncr.30558","article-title":"Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation","volume":"123","author":"Nicolini","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2022.03.009_bib0017","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.bbmt.2016.03.012","article-title":"Allogeneic stem cell transplantation for patients with T315I BCR-ABL mutated chronic myeloid leukemia","volume":"22","author":"Xu","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.009_bib0018","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1182\/blood-2006-01-015347","article-title":"Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study","volume":"109","author":"Ray","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.03.009_bib0019","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.03.009_bib0020","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.03.009_bib0021","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.009_bib0022","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.009_bib0023","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","article-title":"Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients","volume":"69","author":"Shulman","year":"1980","journal-title":"Am J Med"},{"key":"10.1016\/j.jtct.2022.03.009_bib0024","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.009_bib0025","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.03.009_bib0026","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.03.009_bib0027","doi-asserted-by":"crossref","first-page":"984","DOI":"10.6004\/jnccn.2009.0065","article-title":"NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia","volume":"7","author":"O'Brien","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jtct.2022.03.009_bib0028","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s12185-017-2330-1","article-title":"JSH guideline for tumors of hematopoietic and lymphoid tissues-leukemia: 4. Chronic myelogenous leukemia (CML)\/myeloproliferative neoplasms (MPN)","volume":"106","author":"Usui","year":"2017","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2022.03.009_bib0029","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1007\/s00277-020-04212-1","article-title":"The impacts of BCR-ABL1 mutations in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation","volume":"99","author":"Tachibana","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2022.03.009_bib0030","first-page":"513","volume":"91","author":"Gratwohl","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.03.009_bib0031","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1038\/s41409-019-0513-5","article-title":"Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry","volume":"54","author":"L\u00fcbking","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.009_bib0032","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/ajh.24793","article-title":"Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia","volume":"92","author":"Kondo","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2022.03.009_bib0033","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13045-021-01055-9","article-title":"Third-line therapy for chronic myeloid leukemia: current status and future directions","volume":"14","author":"Cortes","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtct.2022.03.009_bib0034","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3389\/fonc.2019.00088","article-title":"Impact of additional chromosomal aberrations on the disease progression of chronic myelogenous leukemia","volume":"9","author":"Krishna Chandran","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtct.2022.03.009_bib0035","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2016-01-690230","article-title":"Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy","volume":"27","author":"Wang","year":"2016","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722001567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722001567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:02:58Z","timestamp":1763002978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722001567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2666636722001567"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.03.009","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Clinical Significance of BCR-ABL1 Mutations in Patients With Philadelphia Chromosome\u2013Positive Chronic Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}